Findings from a new study show that time-to-treatment, at least in the short term, is not significantly associated with adverse outcomes in patients with high-risk prostate cancer. Eric Klein, MD, Chair of the Glickman Urological and Kidney Institute and a co-author of the study, comments on the implications of these findings.
A new study finds neoadjuvant and adjuvant monotherapy using the checkpoint inhibitor durvalumab is well-tolerated by patients with locally advanced renal cell carcinoma, but adding a second checkpoint inhibitor, tremelimumab, caused complications that forced some patients to discontinue the combination therapy.
What research abstracts presented at this year’s American Society of Clinical Oncology annual meeting will have the biggest potential impact on clinical practice? Cleveland Clinic Cancer Center physicians make their picks.